Oral cephem antibiotics are commonly used to treat children with acute upper respiratory tract infection. We studied the efficacy, safety, and compliance of a five-day three-dose regimen of cefdinir(CFDN) fine granules at 15 mg/kg daily or cefcapene pivoxil(CFPN-PI) fine granules at 9 mg/kg daily. Because a new improved formulation of CFPN-PI fine granules was introduced by the manufacturer during the study, period we divided the study into period I from January to September 2004, and period II, from October 2004 to April 2006. In period I, CFDN fine granules were administered to 33 patients and CFPN-PI to 36 patients. In period II, each drug was administered to 50 patients. Therapeutic efficacy was calculated based on changes in body temperature and the rate of improvement in clinical symptoms. Efficacy was 100% for period I and 92% for period II in the CFDN group and 100% for period I and 86% for period II in the CFPN-PI group. No significant difference was seen between groups. Soft stool and diarrhea were side effects noted in both groups. For the CFDN group, the incidence of side effects was 12% for period I and 18% for period II. For the CFPN-PI group, the incidence was 14% for period I and 32% for period II, with no significant difference between groups. When we examined compliance, all doses were taken without problem in 81% of the CFDN-treated patients in period I and 83% in period II, and in 57% of the CFPN-PI-treated patients in period I and 67% period II. Although the improved CFPN-PI fine granule formulation demonstrated better compliance than the older formulation, compliance was significantly better in the CFDN group than the CFPN-PI group (p < 0.05). We therefore confirmed the high efficacy and safety of both CFDN fine granule and CFPN-PI fine granule formulations for the treatment of acute upper respiratory tract infections in children. We concluded that CFDN fine granules was a particularly useful therapy because compliance is an important consideration when treating younger children.
|Number of pages||6|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 2007 Jul 1|
- Upper respiratory tract infection
ASJC Scopus subject areas
- Pharmacology (medical)